Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Accumulated Expenses (2022 - 2025)

BioXcel Therapeutics has reported Accumulated Expenses over the past 4 years, most recently at $4.3 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $4.3 million for Q4 2025, up 619.9% from a year ago — trailing twelve months through Dec 2025 was $4.3 million (up 619.9% YoY), and the annual figure for FY2025 was $4.3 million, up 619.9%.
  • Accumulated Expenses for Q4 2025 was $4.3 million at BioXcel Therapeutics, up from $3.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for BTAI hit a ceiling of $18.7 million in Q4 2022 and a floor of $21000.0 in Q1 2025.
  • Median Accumulated Expenses over the past 4 years was $3.1 million (2023), compared with a mean of $5.3 million.
  • Biggest five-year swings in Accumulated Expenses: crashed 97.46% in 2024 and later skyrocketed 3786.08% in 2025.
  • BioXcel Therapeutics' Accumulated Expenses stood at $18.7 million in 2022, then plummeted by 33.45% to $12.4 million in 2023, then crashed by 95.15% to $603000.0 in 2024, then surged by 619.9% to $4.3 million in 2025.
  • The last three reported values for Accumulated Expenses were $4.3 million (Q4 2025), $3.1 million (Q2 2025), and $21000.0 (Q1 2025) per Business Quant data.